It serves mainly the domestic and US market, primarily supplying cadmium zinc telluride-based detectors.

That’s a relatively niche market, which can be both advantagous and problematic. While it’s unlikely to face stiff competition, demand for its products could drop sharply if conditions change.

But for now, it seems to be doing very well. Let’s take a closer look.

Lofty growth expectations

The share price has soared 103% in the past 12 months, driven largely by strong H1 results covering the six months to 31 October 2025.

And analysts following the stock don’t think it’s done. They expect further growth, with an ambitious 12-month target of 22.5p — a 106% rise!

But is it realistic to expect the shares to double in value again by next April?

Before getting too excited, I decided to take a closer look.

In demand

What I like about Kromek is that it actually has fairly decent earnings visibility for a penny stock. Its near-term revenue pipeline is substantial, with deals in place worth upward of $20m for 2026.

This momentum’s driven by expanded distribution in 39 new countries across Europe, the Middle East and Asia.

In H1 2026, it reported £15m in revenue — up from £3.7m — with management guiding for £60m by 2030. That’s an ambitious target, but is it backed by evidence of prevailing demand?

These notable orders and contract wins seem to suggest so:

• £4.8m orders globally.
• A $37.5m deal with Siemens Healthineers.
• A £1.7m, four-year Radiological Nuclear Detection Framework with the UK MoD.
• Additional nuclear security orders from UK/Europe, US, Japan, and Canada worth £2.9m.
• Multi-year bio-security contracts in the US.

So it’s a profitable, growing business that appears to be in high demand. What’s the catch?

Risks

Micro-cap stocks always face higher risk than larger companies, and Komek’s no stranger to that. Supply chain issues and reliance on debt are key challenges that the group has struggled with in the past.

It still carries £4.62m in debt and needs to maintain high cash flow to keep operating. Any significant contract loss or delayed order could throw it off track. Plus, penny stocks are thinly traded, which adds liquidity risk for shareholders. 

Still, with £56.88m in equity and a return on equity (ROE) of 25%, I wouldn’t say it’s struggling.

My verdict

Penny stocks always require a bit more faith than larger-caps, with the high reward potential coming with a big dollop of risk. More often than not, assessing them feels like trying to see in the dark. But for Kromek Group, its forecast price growth’s backed by real-world use cases and steady demand.

Aside from a steady medical imaging orderbook, the growing threat of nuclear instability in the Middle East will likely boost demand.

Like any micro-cap, it’s not something to go all in on. But with growing demand and promising forecasts, it’s worth considering as a small allocation. 

The post After a 103% gain, this penny stock’s forecast to rise a further 106%. But will it? appeared first on The Twelfth Magpie.

That’s obviously a significantly higher return than the FTSE 100 or any other index.

Zooming further out though, the picture’s not as rosy as the Kromek share price is 60% lower than a decade ago. The small-cap company doesn’t pay dividends, so this longer-term underperformance is disappointing

Nevertheless, the under-the-radar stock clearly has strong momentum right now. So, might it be worth a closer look?

The firm at a glance

Kromek makes high-performance radiation and bio-detection technology products for two global markets: advanced imaging and chemical, biological, radiological, and nuclear (CBRN) detection.

In advanced imaging, the firm is a key supplier of CZT-based detector modules. These significantly improved the quality of medical imaging, with lower patient radiation doses. CZT (cadmium zinc telluride) is a crystalline semiconductor material used to detect radiation.

Its CBRN business consists of handheld devices used for gamma-ray detection and isotope analysis in complex nuclear environments. These are widely deployed in nuclear power stations and increasingly in homeland defence.

Why are investors bullish?

Turning to the financials, it’s easy to see why the share price has done well. Kromek has real business momentum, with revenue rocketing 305% to £15m in the six months to 31 October.

This figure was boosted significantly by a major licencing deal signed with Siemens Healthineers in January 2025. The contract was worth $37.5m (£29.5m) over four years, pushing the group into profitability for the first time.

Even without this deal though, advanced imaging revenue increased 41% to £2.5m, while CBRN detection revenue more than doubled to £4.3m. Gross margin improved dramatically to 71.7% from 56.9%, helping the firm swing from a £5.7m loss to a pre-tax profit of £3.1m.

CEO Dr Arnab Basu said: “With robust customer engagement and a good order book, we expect the momentum achieved in H1 to continue. As a result, we remain on track to deliver a full-year performance in line with market expectations.”

For FY26 (ending April), the market expects £27.1m in revenue, with a net profit of £2.5m. Revenue was £13.1m in FY20.

Medium-term targets

Now, it goes without saying that investing in a small £78m-cap posting a £2.5m profit adds significant risk. With such a slender margin, it wouldn’t take much to tip Kromek back into the red.

For example, the business could be hit with global supply chain constraints that push costs up or delay production. Also, large contracts like the Siemens Healthineers one can result in lumpiness in the financial results.

However, taking a longer-term view, I’m quite bullish here. Kromek should win more contracts as nuclear comes back into fashion. After all, growth of nuclear power necessitates more monitoring for public safety.

Crucially, the Siemens Healthineers deal was on a non-exclusive basis. So Kromek is free to supply its IP to other manufacturers in advanced imaging markets as it aims for over £60m in revenue and a 30% EBITDA margin in the medium term.

Finally, Kromek’s price-to-sales ratio of 2 isn’t particularly high. Putting all this together then, I think this penny stock is worth further research by adventurous investors. A grand currently buys 8,403 shares.

The post £1,000 buys 8,403 shares of this red-hot penny stock that’s smashing the FTSE 100 appeared first on The Twelfth Magpie.

There are a number of small-cap UK defence stocks that have delivered far higher returns over the last six months, however. Here are three to check out.

Advanced space technology

First up, we have Filtronic (LSE: FTC), which is up about 50% over the last six months. This is a technology company that specialises in advanced wireless communication solutions.

It’s had a lot of success in recent years selling wireless components to SpaceX. It’s now having success selling satellite and sensor hardware to defence businesses.

For example, in December, the company won a £11m contract with a major defence prime. “This latest win deepens our engagement with a key European defence customer and strengthens Filtronic’s position in the defence sector, a growing market for the group,” said CEO Nat Edington at the time.

After its recent run up, this stock looks a little expensive. The forward-looking price-to-earnings (P/E) ratio is now over 50 – this doesn’t leave any room for an operational setback (eg the loss of a key customer).

Taking a five-year view, however, I see a lot of potential. So, I think the stock is worth considering.

Nuclear radiation protection

Next, we have Kromek (LSE: KMK), which is up about 150% over six months. It provides nuclear radiation detection solutions to the global defence and security markets.

Its product portfolio ranges from personal, handheld, and wearable devices to systems that can be mounted on remotely operated vehicles (ROVs) or drones. Note that the company has worked in partnership with the US Department of Defense’s Defense Threat Reduction Agency (DTRA) and the Defense Advanced Research Projects Agency (DARPA) to develop high quality products and solutions that meet the needs of leading players in the defence and security industries.

I think this company has a lot of growth potential and is worth a closer look. It could do well in the years ahead as governments spend more on defence (note that sales in its chemical, biological, radiological, and nuclear defence (CBRN) segment more than doubled in the first half of the current financial year).

That said, this is a very small business and profits could be up and down. So, the stock could be volatile.

Rugged computing products

Finally, we have Concurrent Technologies (LSE: CNC), which is up about 50% over six months. It makes rugged high-performance computing products designed for the defence and aerospace markets.

This company has a lot of momentum at present. In January, it told investors that it generated double-digit growth for 2025 and that total order intake for FY25 was a record £47m (versus £41m in 2024).

It added that it has started 2026 with good momentum, underpinned by robust customer demand, record order intake, and a growing pipeline of design wins that are expected to convert into production revenues. This all sounds very promising.

The forward-looking P/E here is about 35, so again, we have an expensive stock that doesn’t have a lot of room for error. However, with earnings per share expected to grow by around 20% this year, it could still be worth a look.

The post 3 small-cap UK defence shares that are crushing BAE Systems and Rolls-Royce appeared first on The Twelfth Magpie.

However, over the last six months, another FTSE defence stock has outperformed these two names by an enormous margin. Could it be worth a closer look right now?

A UK defence stock no one has heard of

The stock I want to highlight here is Kromek (LSE: KMK). It’s a small British company that provides nuclear radiation detection solutions to the global homeland defence and security markets.

It’s known for its compact, handheld, high-performance radiation detectors. These are used to protect urban environments and critical infrastructure from the threat of ‘dirty bombs’.

An AIM-listed penny stock (it’s a member of the FTSE AIM All Share index), Kromek currently trades for just 9.3p. That means that a £1,000 investment would buy around 10,750 shares.

In terms of performance, the stock has experienced a pullback in recent weeks. However, over the last six months, it has surged around 80%, leaving Rolls-Royce and BAE Systems shares in its dust.

Long-term growth potential

Now, penny stocks like this are risky investments. Often, their share prices swing around wildly.

However, taking a long-term view, I see a fair bit of potential here. Given the company’s defence and national security exposure, there’s plenty of scope for revenue growth.

This side of the business has certainly been performing well recently. In the six-month period to the end of October 2025, sales in the company’s chemical, biological, radiological, and nuclear defence (CBRN) division more than doubled to £4.3m, reflecting the growing global focus on national security.

Note that in the company’s H1 results, published in January, it said that in the current year to date, it had received new CBRN detection orders worth £4.8m. These were from customers across the UK, Europe, the US, Japan, Canada, and Australasia.

Medical revenues too

I’ll point out this company is not just a play on defence. It also provides advanced imaging solutions for the healthcare and industrial industries.

Recently, revenues in the company’s advanced imaging division have been boosted by a major deal with Siemens Healthineers. This deal will see Kromek provide cadmium zinc telluride (CZT) detectors for SPECT (single-photon emission computed tomography) imaging.

Tipped to rise 170%

While this is all exciting, I want to stress that this is a high-risk stock. Looking ahead, major contracts could be sporadic in nature meaning that growth won’t be linear.

Profitability is another risk to consider. This is a small company (market cap of £63m) so I’d expect its profits to be volatile.

I think it’s worthy of further research, however. Note that the average broker price target is 26p – about 180% above the current share price.

The post £1,000 buys 10,750 shares in this red-hot FTSE defence stock that’s crushing Rolls-Royce and BAE Systems appeared first on The Twelfth Magpie.

Now analysts’ forecasts need to be taken with a grain of salt – there are a lot of duds among the 60 shares that realistically have little chance of doubling (or even doing well). But what I thought I’d do is filter the list of stocks for those that have relatively strong momentum (both price momentum and earnings momentum) to identify some potential winners.

A UK defence stock that isn’t on mainstream radars

After this filter, one stock that immediately jumped out at me was Kromek Group (LSE: KMK). It develops radiation detection solutions for a range of markets including security and defence, civil nuclear, and biological detection.

The company’s exposure to defence is what excites me here. The defence industry’s booming right now and I can see Kromek benefitting from increased government spending in the years ahead as radiation detection is vital for the safety of both civilians and soldiers.

Note that last year, the company won a £1.7m contract from the UK government. This was for the procurement of radiological nuclear detection equipment and supporting services for the Home Office.

Looking at Kromek’s financials, revenues are on the up. For the year ending 30 April, revenue’s expected to be £27.1m versus £10.4m five years earlier.

That said, the company’s only recently become profitable and, as a result, its price-to-earnings (P/E) ratio’s quite high. So a doubling of the share price in 2026 is far from guaranteed.

One other thing worth pointing out is that recent growth here has been driven by a large contract win with Siemens Healthineers. There’s a risk that in the near term, growth moderates due to a lack of large deals like this.

I think this stock is worth a closer look however. The average price target is 26p versus today’s share price of 10p.

A deep-value opportunity in the small-cap space

Another stock that looks interesting to me is Water Intelligence (LSE: WATR). It provides tech-driven leak detection solutions for residential, commercial and municipal customers and is therefore a play on the sustainability theme.

This stock’s currently trading near 315p. However, the average price target is about 678p (115% higher).

Looking at Water Intelligence’s most recent trading update, the company has quite a bit of momentum right now. For the third quarter of 2025, revenue increased 11% year on year to $24.3m while adjusted pre-tax profit was up 68% to $2.8m.

“We had a strong Q3 in terms of both revenue and profits which builds upon the momentum from Q2.”

Water Intelligence executive chairman Dr Patrick DeSouza

This momentum isn’t reflected in the valuation though. Currently, the stock trades on a P/E ratio of just nine, so there’s scope for a materially-upward valuation re-rating here.

A risk with this stock is debt. In recent years, the company has made a number of acquisitions and this has weakened its balance sheet.

At the current valuation however, the risk/reward set-up looks attractive, in my view. I think this small-cap stock’s worthy of further research.

The post 2 exciting UK stocks tipped to double in 2026 appeared first on The Twelfth Magpie.

Looking ahead, further challenges could be ahead for the UK retail sector. But with the stock having what appears to be a sound growth outlook, it could be worth a closer look alongside a smaller stock that reported positive news on Monday.

Growth potential

The company in question is radiation detection technology firm Kromek (LSE: KMK). It announced news of a new long-term supply contract worth a minimum of $7.8m for an existing customer within the baggage security screening market. The contract covers a five-year period and starts immediately.

Today’s news follows other multi-year contracts as customers continue to embrace new technology, with the company appearing to be well-placed to capitalise on growing demand at a time when security is becoming an increasingly important factor for a range of organisations. The company’s ability to deliver customer-specific detector modules and deploy them in advanced screening systems for real-world use could mean that demand for its products remains high.

Although Kromek is expected to remain loss-making in the next two financial years, the long-term prospects for the business could be relatively bright. While potentially risky, it could deliver high rewards over the long run. As such, it may be worthy of consideration for less risk-averse investors.

Improving prospects

As mentioned, Morrisons has undergone a transformation in recent years. The company has been able to increase its exposure to the wholesale industry, with it seeking to build on its status as a major food producer and distributor. This has helped the business to gain additional exposure to faster-growing areas such as convenience and online opportunities, where previously it had arguably been behind some of its industry peers.

As well as this, the company has expanded areas such as its loyalty programme, while also increasing staff pay as it seeks to deliver an improved customer experience. With a special dividend having been paid in the last two financial years, the company’s management appears to have confidence in its future growth outlook.

Although the prospects for the UK food retail industry remain somewhat challenging, the outlook for Morrisons could be relatively positive. The company is forecast to post a rise in earnings of 8% in the current year, followed by further growth of 10% next year. As such, it seems to have a bright future ahead of it, with its revised strategy appearing to offer a strong catalyst for its financial performance.

While there could be further uncertainty ahead for a variety of retail shares in the UK, the company appears to have found the right plan through which to outperform the FTSE 100 in the long run, in my opinion.

The post Why I think there has never been a better time to buy FTSE 100 member Morrisons’ share price appeared first on The Twelfth Magpie.

I last wrote about the company in December when it reported 27% revenue growth in the first half of its financial year. It said it was well positioned to achieve EBITDA break-even for the full year. The shares were trading at 25p at the time and I rated the stock a ‘buy’ on its valuation of 5.2 times forecast full-year revenue. How has the company performed since, and is the valuation still attractive today?

Highly lucrative prospects

The full-year results saw Kromek’s revenue growth accelerate to 32%, with £11.85m booked on the top line, and a £0.5m maiden EBITDA profit. Net cash at the year end (30 April) was £6.5m. The revenue growth was driven by continued delivery on previously-signed agreements, as well as commencing delivery on new high-value contracts won during the year. The company also continued to protect its technology, filing seven new patents and having 29 granted during the period.

Contract news since the year end has been strong. The latest announcement (today), is that the US Defense Threat Reduction Agency is funding Kromek to the tune of $1.8m to develop a next-generation military-grade version of its civilian D3S handheld radiation detection device. If successful, I believe commercial follow-on orders, not only from the US, but also potentially NATO, could be highly lucrative.

Kromek’s shares are up 7.5% to 28.5p today, giving the company a market capitalisation of £74.2m. This is 4.9 times current-year forecast revenue of £15.05m — a cheaper rating than when I wrote about the stock last year. As such, I continue to rate it a ‘buy’.

Good buying opportunity

Fellow AIM-listed small-cap Gear4music (LSE: G4M) is ahead of Kromek in its development. Revenue is expected to burst through the £100m level this year and at a current share price of 517p, the company’s market capitalisation is £108m. However, it’s still at a relatively early stage of growth and is another business I’d happily buy a slice of for its terrific potential.

Gear4music is already the largest UK-based online retailer of musical instruments and music equipment but it’s also rapidly increasing its international reach. In its last financial year (to 28 February), the UK contributed £44.3m to group revenue (up 27% on the previous year) and International contributed £35.8m (up 69%).

It was a year of heavy investment for the company but net debt at the year end was a modest £5m and the investment in the business gives it a platform for further strong growth. City analysts are forecasting annual earnings increases of over 50% this year and next. The share price got as high as 865p last October and I believe the decline to the current 517p represents a good opportunity to buy in. The valuation is still a premium one — 50 times this year’s earnings, falling to 32 times next year’s — but I reckon the growth potential is such that the rating is more than merited.

The post 2 high-growth stocks that are just getting started appeared first on The Twelfth Magpie.

Growing reputation

The company designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets. The period under review saw higher product sales across these key markets, as well as the continued winning of new high-value contracts.

Its D3S product, which it describes as “the world’s most advanced, portable, nuclear radiation detection device,” was successfully deployed in high-profile situations for safeguarding against nuclear terrorism, including the NATO Security Summit and Donald Trump’s visit to Brussels in May. And the company also enjoyed reputation-enhancing successes in its other key markets.

Attractive valuation?

Analysts are forecasting revenue of £12.5m for the full year (almost 40% ahead of last year) and Kromek appears to have substantial commercial opportunities in the medium and long term, including from an $8.2bn US Department of Defence security programme.

The shares have fallen quite heavily on today’s results — down 8% at 25p, as I’m writing. This values the AIM-listed firm at £65m, which is 5.2 times forecast revenue. Personally, I view this as an attractive multiple and rate the stock a ‘buy’, albeit a risky one, due to it being an early-growth and currently lossmaking business. Risk-averse investors may want to monitor progress from the sidelines for the time being.

I put today’s share price fall partly down to the inherent volatility of small-caps and partly down to the fact that, while Kromek is moving rapidly towards EBITDA breakeven, cash burn in the first half was £5.3m. However, I note that £3.7m of this was investment in development and working capital and that the company is well funded for the year ahead with net cash on the balance sheet of £12m.

Terrific buy?

Fellow AIM-listed firm Idox (LSE: IDOX) is already profitable, and has been for a good number of years. However, recent problems have seen its shares collapse 58% from 65p to 27p in the space of just over five weeks.

On 14 November, in a trading update for its financial year ended 31 October, the software provider, which counts over 90% of UK local authorities among its customers, said sign-off on some contract wins had been delayed beyond the end of the financial year due to customer disruption in the wake of June’s General Election.

This was hardly the end of the world, as the board’s lowered EBITDA expectation of £23m was still above the prior year’s £21.5m. However, in a further trading update on 13 December, it lowered its expectation to £20m. This was due to an internal review in preparation for the full-year audit identifying “a small number of revenue items that it does not consider should be recognised in the FY2017 results.” It added that “clarification of these issues has been complicated by the sudden absence of Andrew Riley, Idox’s CEO, due to illness.”

The stock could prove a terrific buy at the current level but the nature of the news is disconcerting enough to persuade me to wait for the company’s final results in February.

The post 2 secret growth stocks to watch in 2018 appeared first on The Twelfth Magpie.

Ramping up revenues

Kromek is a radiation detection technology company focused on the medical, security screening and nuclear markets. It said 2016/17 was “another year of good progress and ramp-up in commercial activities with revenue growth driven by higher product sales across [its] three key target markets.”

Revenue for the year increased 7.5% to £9m but 2017/18 will see a step change as revenue comes through on large-scale contracts that have been secured over the last 24 months. Management said: “The group expects to report year-on-year revenue growth of approximately 40%, in line with market expectations.” So we’re looking at about £12.6m.

Kromek isn’t currently profitable, reporting a £3.1m bottom-line loss today, having expensed £3.5m of research costs for products and platforms that it said are “linked to existing contract deliverables and significant future revenue opportunities.”

The company had cash of more than £20m on its balance sheet at year-end (thanks to a fundraising in January) and has a good number of institutional investors on its shareholder register. While the cash pile means I’m unconcerned by Kromek’s current lossmaking status, it also means I have to value it on revenue rather than profit at this stage.

Valuation

At the current share price of 33p, the market capitalisation is £85m, so the stock trades at 6.8 times next year’s guided revenue of £12.6m. This looks an enticing multiple to me for an early-growth business, whose advanced patent-protected technologies are gaining increasing traction in the attractive medical, security screening and nuclear markets.

The shares appear very buyable to my eye, although as a higher-risk investment this is a stock I would only take a small stake in at this stage of its development.

Demographics growth driver

ConvaTec (LSE: CTEC) is another stock in the health sector I’ve got my eye on. This FTSE 100 firm is a lower-risk proposition than Kromek but, like the small-cap, its share price has fallen back somewhat after a strong run. ConvaTec’s shares climbed from 234p at the start of the year to a high of 344p but are currently trading at 327p.

In a Q1 trading update released last month, the company reported revenue growth in its Advanced Wound Care and Ostomy Care divisions of 4.2% and 3.3% respectively. It saw flat revenue in Continence & Critical Care (due to margin improvement measures) and a 3.1% decline in Infusion Devices division (due to anticipated customer inventory reductions). But management reaffirmed its previous guidance for 2017 of group organic revenue growth in excess of 4% at constant currency.

On the back of this, the City consensus is for ConvaTec to deliver earnings per share of $0.20 (15.6p), giving a price-to-earnings ratio of 21. This is not a premium rating by the sector standards and with demographics providing a long-term driver for growth, the shares appear to be an attractive buy.

The post Why I’d buy these 2 rising health stocks appeared first on The Twelfth Magpie.

Improving outlook

Reporting on Friday was radiation detection technology company Kromek (LSE: KMK). Its shares increased in price by over 8% following the update, which shows that investor sentiment continues to improve. This takes the company’s gain in 2017 to around 29% versus just 1.5% for the FTSE 100.

Kromek’s update stated that it is making good progress on the delivery of new orders won over the past two years. Due to this, it is continuing to trade in line with expectations. Its products have gained traction in all of its business segments from the increasing adoption of CZT-based technology and other products. More customer wins are expected in future, with Kromek anticipating a step change in revenue in the new financial year.

In fact, the company is expected to report a narrowing of the losses of recent years. Following a pre-tax loss of £4.1m in 2016, it is due to post a pre-tax loss of £3.7m in financial year 2017. This is then expected to narrow to a loss of £2.1m in financial year 2018. Given it has taken part in a successful fundraising and investor sentiment seems to be on the up, now could be the right time to buy a slice of the business.

Recovery potential

Also offering FTSE 100-beating performance is Judges Scientific (LSE: JDG). The scientific instrument business has experienced a difficult period of late, with its bottom line being highly volatile and causing its share price to disappoint somewhat. However, since the start of the year there has been an improvement in investor sentiment, with the company’s shares rising by 20% year-to-date.

Looking ahead, more growth could be on the horizon. Judges Scientific is expected to deliver a rise in its bottom line of 24% in the current year, followed by additional growth of 12% next year. Since investors are understandably somewhat cautious about its prospects owing to its disappointing profit falls in recent years, the company has a relatively wide margin of safety at the present time. It trades on a price-to-earnings growth (PEG) ratio of just 1.1, which indicates that it offers a favourable risk/reward ratio.

Of course, there is no guarantee that Judges Scientific will deliver on its upbeat forecasts. However, the company seems to have turned a corner and now has the right strategy through which to improve on its rising share price.

The post 2 rising small caps set to beat the FTSE 100 appeared first on The Twelfth Magpie.